Third Harmonic Bio Inc. (THRD) NASDAQ
$9.44 (0.03) (-0.32%)
Market Cap: $385.57M
As of 03/28/24 04:00 PM EDT. Market closed.
Third Harmonic Bio Inc. (THRD)
NASDAQ
$9.44
(0.03) (-0.32%)
Market Cap: $385.57M
As of 03/28/24 04:00 PM EDT. Market closed.
third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation ... read more
third harmonic bio is a clinical-stage company developing a highly selective, oral kit inhibitor for treatment of severe allergy and inflammation. kit is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. our lead product candidate, thb001, is the first highly selective, oral small-molecule kit inhibitor to enter clinical development. with promising drug-like properties and an encouraging early clinical profile, thb001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Person Julie | Chief Administrative Officer | Dec 05, 2023 | Option Exercise | $4.20 | 12,863 | 54,025 | 12,863 | Dec 07, 2023, 04:04 PM |
Person Julie | Chief Administrative Officer | Dec 05, 2023 | Sale | $10.30 | 12,863 | 132,484 | 0 | Dec 07, 2023, 04:04 PM |
Conner Edward R. | Chief Medical Officer | Dec 05, 2023 | Option Exercise | $4.20 | 4,790 | 20,118 | 4,790 | Dec 07, 2023, 04:03 PM |
Conner Edward R. | Chief Medical Officer | Dec 05, 2023 | Sale | $10.03 | 4,790 | 48,062 | 0 | Dec 07, 2023, 04:03 PM |
BVF PARTNERS L P/IL | 10% Owner | Dec 20, 2022 | Buy | $4.11 | 214,063 | 879,499 | 2,332,638 | Dec 22, 2022, 06:49 PM |
ORBIMED ADVISORS LLC | Director | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 5,779,071 | Sep 21, 2022, 06:00 PM |
Bonita David P | Director | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 5,779,071 | Sep 21, 2022, 05:59 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Sep 19, 2022 | Buy | $17.00 | 300,000 | 5,100,000 | 10,313,763 | Sep 19, 2022, 04:51 PM |
Owner | Relationship | Date | Value($) |
Person Julie | Chief Administrative Officer | 12/05/2023 | 54,025 |
Person Julie | Chief Administrative Officer | 12/05/2023 | 132,484 |
Conner Edward R. | Chief Medical Officer | 12/05/2023 | 20,118 |
Conner Edward R. | Chief Medical Officer | 12/05/2023 | 48,062 |
BVF PARTNERS L P/IL | 10% Owner | 12/20/2022 | 879,499 |
ORBIMED ADVISORS LLC | Director | 09/19/2022 | 5,100,000 |
Bonita David P | Director | 09/19/2022 | 5,100,000 |
Atlas Venture Fund XI, L.P. | 10% Owner | 09/19/2022 | 5,100,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 5,779,071 | 1.27% | No change | Other |
RA CAPITAL MANAGEMENT, L.P. | 2,033,056 | 0.35% | 111.37% | Other |
BLACKROCK INC. | 1,389,178 | 0.00039% | 20.05% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 400,693 | 0.00046% | 10.95% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 152,027 | 0.00345% | -20.83% | Other |
UBS OCONNOR LLC | 64,704 | 0.05% | -48.24% | Value |
D. E. SHAW & CO., INC. | 26,761 | 0.00026% | New | Other |
RENAISSANCE TECHNOLOGIES LLC | 13,000 | 0.00022% | New | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View